



## **AnteoBind™ - Nano Kit**

(For particles < 0.5  $\mu\text{m}$ )



AnteoTech Ltd  
Unit 4, 26 Brandl Street,  
Eight Mile Plains, Queensland, 4113  
Australia














For research use only.  
Not for use in diagnostic procedures



## Symbol Glossary

The following symbols can be found on kit packaging and components and throughout this instruction for use:

Symbol	Meaning	Symbol	Meaning
	Identifies the catalogue number.		Identifies the batch or lot code.
	Identifies the manufacturer of the kit.		Indicates the maximum and minimum storage temperature limits.
	Indicates the volume of the kit component.		Indicates the kit expiration date.
	Indicates that the kit is for research use only.		Indicates that the instructions for use shall be consulted.
	<b>GHS08 – Health Hazard:</b> Chronic health hazards; this may include aspiratory and respiratory hazards, carcinogenicity, mutagenicity, and reproductive toxicity.		<b>GHS05 – Corrosion:</b> Corrosive chemicals, may cause severe skin and eye damage and may be corrosive to metals.
	<b>GHS07 – Exclamation mark:</b> Low level toxicity. This includes respiratory, skin, and eye irritation, skin sensitisers and chemicals harmful if swallowed, inhaled or in contact with skin.		

## Warnings and Precautions

1. The Instruction for Use (IFU) must be read and understood prior to commencing the use of this kit.
2. For research use only. Not for use in diagnostics procedures.
3. Kit Safety Data Sheet (SDS) is available by contacting AnteoTech Technical Support.
4. Buffers contain ProClin™ 300 or sodium azide as preservatives.
5. Wear appropriate personal protective equipment when using this kit.
6. Follow institutional safety procedures for working with chemicals and handling biological samples.
7. Handle waste as per institutional procedures and in accordance with local regulations.
8. Always protect photosensitive particles from light.
9. Do not use the kit beyond the expiration date.

## AnteoTech Technical Support

For assistance and support please contact AnteoTech Technical Support for guidance.

**Telephone:** +61 7 3219 0085

**Email:** [support@anteotech.com](mailto:support@anteotech.com)

For additional information, visit our website [www.anteotech.com](http://www.anteotech.com)

This IFU may be updated periodically. To ensure that you have the current version, please visit <https://www.anteotech.com/life-science/products/> or contact AnteoTech Technical Support.




## Description

The Nano Kit contains the reagents necessary to activate carboxylated particles < 0.5 µm in diameter with AnteoBind™ and to then conjugate biomolecules to the activated particles. AnteoBind™ is a molecular glue comprised of polymeric metal ions that facilitates conjugation via the utilisation of co-ordination avidity binding between synthetic surfaces and biomolecules. The result is a simplified conjugation process that provides native and secure biomolecule binding.

The Nano Kit contains enough reagent to conjugate a total of 10 mg of particles. This kit can be used to perform conjugations at scales ranging from 0.2 to 10 mg of particles per reaction. This kit contains an optimised buffer set that allows the user to focus on the vital elements of conjugation optimisation. By removing the requirement of buffer optimisation, the kit allows users developing novel assays to perform numerous small-scale conjugations to test multiple conjugation and blocking parameters. The conjugated particles can then be used in particle-based assays, such as, but not limited to Lateral Flow Immunoassays.


Due to the vast diversity of biomolecule composition, conjugation performance is not guaranteed and must be optimised by the end user. For assistance and support regarding biomolecule conjugation please contact AnteoTech Technical Support.

## Principles of AnteoBind™



**Image left:** Schematic representation of AnteoBind functioning as a molecular glue, facilitating the conjugation of synthetic surfaces and biomolecules.

The conjugation process involves two major steps, particle activation with AnteoBind and AnteoBind enabled biomolecule conjugation. The AnteoBind technology takes advantage of supramolecular chemistry, that is, the generation of non-covalent bonds between molecules. AnteoBind contains proprietary water based oligomeric metal-ion complexes that creates a nanometre thin molecular glue on the particle surface, in essence 'activating' the particle surface, priming it for native and secure protein binding.



**Image left:** Transmission electron microscope image demonstrating surface activation. This image of an activated gold nanoparticle demonstrates that the surface is coated in approximately 2 nm of AnteoBind and is ready for biomolecule conjugation.

AnteoBind activated particles have been demonstrated to remain stable at 2-8 °C for 1 year. This kit allows the user to either activate particles in bulk or multiple small lots using the same reagents, providing the user with enhanced experimental reproducibility. This differs from EDC chemistry where the chemical components must be used immediately after reconstitution.



## Provided Materials

Component	Reference	Step	Amount provided
Particle Pre-treatment Solution	A-CMPPPS1	<b>Optional Step</b>	1 x 2 mL
Particle Activation Solution	A-CMPPASF1	<b>Step 1</b>	1 x 5 mL
Particle Wash Solution	A-CMPWSF1	<b>Step 2</b>	1 x 15 mL
Conjugation Buffer (pH 6.0)	A-CMPCBF1	<b>Step 2 &amp; 3</b>	2 x 15 mL
Blocker Diluent (pH 6.0)	A-CMPBDF1	<b>Step 4</b>	1 x 15 mL
Storage Buffer (pH 8.0)	A-CMPSBF1	<b>Step 5</b>	1 x 15 mL

## Required Materials – not provided

- Carboxylated particles < 0.5 µm in diameter
- Low binding polypropylene reaction tubes
- Low binding micropipette tips
- Biomolecule prepared in *A-CMPCBF1: Conjugation Buffer*
- Blocker Agent prepared in *A-CMPBDF1: Blocker Diluent*

## Suggested Equipment

Process	Equipment required
Particle dispersion	Ultrasonicator (liquid or solid medium)
Separation of non-magnetic particles	Centrifuge
Separation of magnetic particles	Magnetic tube rack
Solution and buffer transfer/supernatant removal	Micropipettes
Particle incubation	Tube rotator, roller, or mixer
Sample mixing	Vortex mixer
Sample spot centrifugation	Microcentrifuge

## Special Operating Instructions

<b>Biomolecule compatibility</b>	<p>Not compatible with short peptides or small molecules.</p> <p>This kit has been used to conjugate antibodies, antigens, Fab fragments, streptavidin, Protein A/G, fluorescent proteins, and oligonucleotides.</p> <p>Biomolecule compatibility is not guaranteed and must be determined by the user.</p>
<b>Particle compatibility</b>	<p>Particles must be pre-functionalised with carboxyl (-COOH) functional groups.</p> <p>Particles must be activated and conjugated at 2 mg/mL.</p> <p>Particles prone to aggregation may be treated with <i>A-CMPPPS1: Particle Pre-treatment Solution</i> prior to activation. <i>A-CMPPPS1: Particle Pre-treatment Solution</i> contains a large molecular weight, non-ionic surfactant that promotes steric repulsion, preventing particle surface interaction and inhibiting aggregation.</p>




---

	<p>This kit has been used to conjugate biomolecules to Merck Estapor M1 020/50 and F1-Eu-030 (Note: require <i>Optional step: Particle Pre-Treatment</i>), Allrun PM3-020, Thermo Fisher Scientific Fluoro-Max and Opti-Link particles.</p>
<b>Biomolecule concentration</b>	<p>Protein: this kit has been used at ranges of 25 to 200 µg per mg of particles. Oligonucleotide: this kit has been used at 4,000 pmol per mg of particles. Optimal biomolecule concentration may vary depending on particle, conjugate, and assay type and must be determined by the user.</p>
<b>Particle separation</b>	<p>Magnetic particles: magnetic separator required. Separator parameters should be optimised for specific particle types. Non-magnetic particles: centrifugation required. Centrifugation parameters should be optimised for specific particle types.</p>
<b>Particle aggregation</b>	<p>Pipette-mix, vortex-mix and/or ultrasonicate particles until dispersed. Ultrasonication parameters must be optimised for particle and conjugate types. Co-conjugation, the addition of blocker agent during conjugation, may inhibit conjugation induced aggregation. Co-conjugation parameters must be optimised for particle and conjugate types.</p>
<b>Blocker preparation</b>	<p>This kit contains <i>A-CMPBDF1: Blocker Diluent</i> for blocker agent preparation. AnteoTech recommends the use of ≥ 98% pure, protease free bovine serum albumin (BSA) at 10% (w/v) in <i>A-CMPBDF1: Blocker Diluent</i>. The optimal blocker agent may vary between different particles, conjugates, and assay systems and must be optimised by the user.</p>
<b>Scale</b>	<p>This kit has been tested at 0.2 to 10 mg particle amounts.</p>
<b>Conjugated particle storage and stability</b>	<p>If not immediately used AnteoTech recommends storage of conjugated particles at 2-8 °C under continuous gentle agitation (e.g. tube rotator, mixer, or roller at 25 rpm). The user must determine the stability of each conjugated particle type in <i>A-CMPSBF1: Storage Buffer</i>.</p>
<b>Optional particle analysis</b>	<p>It is recommended that particle diameter, polydispersity index and zeta potential is determined prior to <i>Optional step: Particle Pre-Treatment</i> or <i>Step 1: Particle Activation</i> and after <i>Step 2: Activated Particle Wash</i> and after <i>Step 5: Storage of Conjugated Particles</i>.</p> <p>Particle diameter, polydispersity index may be determined via Dynamic Light Scattering analysis and zeta potential may be determined via Laser Doppler Electrophoresis with the following expected characteristics:</p> <ul style="list-style-type: none"><li>• Raw material: low polydispersity index value, negative zeta potential.</li><li>• Activated particles: larger than raw material, low polydispersity index value, positive zeta potential.</li><li>• Conjugated particles: larger than activated material, low polydispersity index, negative zeta potential.</li></ul> <p>The generated data will allow the user to establish particle compatibility with this kit and to determine the effectiveness of the activation and conjugation processes.</p>

---



## Process Workflow



## General Procedure

**The following procedure details the general process for the activation of 1 mg of carboxylated particles < 0.5 µm in diameter with AnteoBind followed by protein conjugation.**

Refer to Special Operating Instructions above prior to the commencement of this procedure.

*Before commencing please note:*

- **Particles must be pre-functionalised with carboxyl (-COOH) functional groups.**
- **Particles must be adjusted to 20 mg/mL prior to activation.**
- **Particles supplied with surfactant in the stock solution should be washed with *Particle Wash Solution* prior to *Step 1: Particle Activation*.**
- Ensure all materials are at room temperature before use.
- Use a micropipette to remove supernatant taking care not to disturb the particle pellet.
- Vortex-mix particles prior to use. Ultrasonicate if required.
- It is recommended that particle diameter, polydispersity index and zeta potential are determined prior to *Optional step: Particle Pre-Treatment* or *Step 1: Particle Activation* and after *Step 2: Activated Particle Wash* and after *Step 5: Storage of Conjugated Particles*.

### Optional step: Particle Pre-Treatment

**Note:** Pre-treatment is only recommended for unstable particles that are prone to aggregation. Particles that are unable to maintain the stability of a colloidal system are generally stored in surfactants, such as but not limited to, Tween-20.

1. Transfer 50 µL (1 mg) of particles to a new reaction tube.
2. Separate the particles until the supernatant becomes clear and remove the supernatant.
3. Transfer 50 µL of *Particle Pre-treatment Solution* to the reaction tube.
4. Vortex-mix and then ultrasonicate until dispersed.



### Step 1: Particle Activation

1. Transfer 450  $\mu\text{L}$  of *Particle Activation Solution* to a new reaction tube.
2. Transfer 50  $\mu\text{L}$  (1 mg) of particles to the reaction tube.
3. Vortex-mix and then ultrasonicate until dispersed.
4. Incubate for a minimum of 1 hour at room temperature under continuous gentle agitation (e.g. tube rotator at 25 rpm).

**Note:** *The optimal incubation period must be determined by the user.*

### Step 2: Activated particle wash

1. Separate the activated particles and remove the supernatant.
2. Add 500  $\mu\text{L}$  of *Particle Wash Solution* to the particles, vortex mix and ultrasonicate until dispersed.
3. Separate the activated particles and remove the supernatant.
4. Add 500  $\mu\text{L}$  of *Conjugation Buffer* to the particles, vortex mix and ultrasonicate until dispersed.
5. Repeat steps 2.3 and 2.4.
6. Separate the activated particles and remove the supernatant.
7. Add 250  $\mu\text{L}$  of *Conjugation Buffer* to the particles, vortex mix and ultrasonicate until dispersed.

### Step 3: Particle Conjugation

1. Prepare conjugate at the required concentration in 250  $\mu\text{L}$  of *Conjugation Buffer*.

**Example 1:** *For conjugation at 25  $\mu\text{g}$  of protein per mg particles, prepare 250  $\mu\text{L}$  of 100  $\mu\text{g}/\text{mL}$  protein.*

**Example 2:** *For conjugation of at 200  $\mu\text{g}$  of protein per mg particles, prepare 250  $\mu\text{L}$  of 800  $\mu\text{g}/\text{mL}$  protein*

2. Add the 250  $\mu\text{L}$  of washed particles to the 250  $\mu\text{L}$  of prepared conjugate. Vortex-mix and ultrasonicate until fully dispersed.
3. Incubate for 1 hour at room temperature under continuous gentle agitation.

**Note:** *Particle aggregation may occur. This may be reversed during Step 5: Storage of Conjugated Particles.*

### Step 4: Particle Blocking

**Note:** *The optimal blocker agent may vary between different particles, proteins, and assay systems.*

**Note:** *AnteoTech recommends using protease free BSA of  $\geq 98\%$  purity at 10% (w/v) in Conjugation Buffer.*

1. Prepare blocker agent at the required concentration in 100  $\mu\text{L}$  of *Blocker Diluent*.
2. Add 50  $\mu\text{L}$  of prepared blocker agent directly to the particle reaction tube.
3. Vortex-mix and ultrasonicate until fully dispersed.
4. Incubate for 1 hour at room temperature under continuous gentle agitation.

**Note:** *Particle aggregation may occur. This may be reversed during Step 5: Storage of Conjugated Particles.*

### Step 5: Storage of Conjugated Particles

1. Separate the activated particles and remove the supernatant.
2. Add 500  $\mu\text{L}$  of Storage Buffer to the particles, vortex mix and ultrasonicate until dispersed.
3. Repeat steps 5.1 and 5.2.
4. Separate the activated particles and remove the supernatant.
5. Add 100  $\mu\text{L}$  of Storage Buffer to the particles, vortex mix and ultrasonicate until dispersed.
6. The particles are approximately 10 mg/mL and are ready for use.

**Note:** *The end user must determine the stability of each conjugate in Storage Buffer.*



## Magnetic particle example procedure 1

The following procedure details AnteoTech's optimised process for the activation of 1 mg of unstable 200 nm superparamagnetic polystyrene particles with AnteoBind followed by Cardiac Troponin monoclonal antibody (cTnI mAb) conjugation.

### Particle Pre-Treatment

1. Determine raw material particle diameter, polydispersity index via Dynamic Light Scattering analysis and zetapotential via Laser Doppler Electrophoresis.
2. Transfer 50  $\mu$ L (1 mg) of 20 mg/mL particles to a 1.7 mL reaction tube.
3. Separate the particles on a magnetic tube rack for 1 minute.
4. Remove and discard the supernatant taking care not to disturb the pellet.
5. Transfer 50  $\mu$ L of *Particle Pre-treatment Solution* to the reaction tube.
6. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the sweet spot of a water bath.

**Note:** The water bath sweet spot is defined as the liquid surface area displaying the most disturbance.

### Step 1: Particle Activation

1. Transfer 450  $\mu$ L of *Particle Activation Solution* to a new reaction tube.
2. Spot centrifuge the pre-treatment reaction tube and then transfer the particles to the *Particle Activation Solution* reaction tube.
3. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 16 hours at room temperature on a tube rotator at 25 rpm.

### Step 2: Activated particle wash

1. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
2. Remove and discard the supernatant taking care not to disturb the pellet.
3. Add 500  $\mu$ L of *Particle Wash Solution* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
5. Remove and discard the supernatant taking care not to disturb the pellet.
6. Add 500  $\mu$ L of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
7. Repeat steps 4 to 6.
8. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
9. Remove and discard the supernatant taking care not to disturb the pellet.
10. Add 250  $\mu$ L of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
11. Determine activated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zetapotential via Laser Doppler Electrophoresis.

### Step 3: Particle Conjugation

1. Prepare 200  $\mu$ g/mL cTnI mAb with 200  $\mu$ g/mL BSA in 250  $\mu$ L of *Conjugation Buffer*.
2. Add the 250  $\mu$ L of washed particles to the 250  $\mu$ L of conjugation solution.
3. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 1 hour at room temperature on a tube rotator at 25 rpm.





#### Step 4: Particle Blocking

1. Prepare 10% (w/v) BSA in *Blocker Diluent*.
2. Add 50 µL of the 10% (w/v) BSA directly to the particle reaction tube.
3. Vortex-mix for 10 seconds and then water bath ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 1 hour at room temperature on a tube rotator at 25 rpm.

#### Step 5: Storage of Conjugated Particles

12. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
13. Remove and discard the supernatant taking care not to disturb the pellet.
14. Add 500 µL of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
15. Repeat steps 1 to 3.
16. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
17. Remove and discard the supernatant taking care not to disturb the pellet.
18. Add 100 µL of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
19. Determine conjugated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zeta potential via Laser Doppler Electrophoresis.
20. The particles are approximately 10 mg/mL and are ready for use.

## Magnetic particle example procedure 2

**The following procedure details AnteoTech's optimised process for the activation of 1 mg of unstable 300 nm superparamagnetic polystyrene particles with AnteoBind followed by Poly dT 30-mer oligonucleotide conjugation.**

#### Particle Pre-Treatment

1. Determine raw material particle diameter, polydispersity index via Dynamic Light Scattering analysis and zeta potential via Laser Doppler Electrophoresis.
2. Transfer 50 µL (1 mg) of 20 mg/mL particles to a 1.7 mL reaction tube.
3. Separate the particles on a magnetic tube rack for 1 minute.
4. Remove and discard the supernatant taking care not to disturb the pellet.
5. Transfer 50 µL of *Particle Pre-treatment Solution* to the reaction tube.
6. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the sweet spot of a water bath.

**Note:** *The water bath sweet spot is defined as the liquid surface area displaying the most disturbance.*

#### Step 1: Particle Activation

1. Transfer 450 µL of *Particle Activation Solution* to a new reaction tube.
2. Spot centrifuge the pre-treatment reaction tube and then transfer the particles to the *Particle Activation Solution* reaction tube.
3. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 16 hours at room temperature on a tube rotator at 25 rpm.



## Step 2: Activated particle wash

1. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
2. Remove and discard the supernatant taking care not to disturb the pellet.
3. Add 500  $\mu$ L of *Particle Wash Solution* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
5. Remove and discard the supernatant taking care not to disturb the pellet.
6. Add 500  $\mu$ L of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
7. Repeat steps 4 to 6.
8. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
9. Remove and discard the supernatant taking care not to disturb the pellet.
10. Add 250  $\mu$ L of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
11. Determine activated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zetapotential via Laser Doppler Electrophoresis.

## Step 3: Particle Conjugation

1. Prepare 16,000 pmol/mL Poly dT 30-mer oligonucleotide in 250  $\mu$ L of *Conjugation Buffer*.
2. Add the 250  $\mu$ L of washed particles to the 250  $\mu$ L of conjugation solution.
3. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 2 hours at room temperature on a tube rotator at 25 rpm.

## Step 4: Particle Blocking

1. Prepare 10% (w/v) BSA in *Blocker Diluent*.
2. Add 50  $\mu$ L of the 10% (w/v) BSA directly to the particle reaction tube.
3. Vortex-mix for 10 seconds and then water bath ultrasonicate for 5 minutes in the water bath sweet spot.
4. Incubate for 1 hour at room temperature on a tube rotator at 25 rpm.

## Step 5: Storage of Conjugated Particles

1. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
2. Remove and discard the supernatant taking care not to disturb the pellet.
3. Add 500  $\mu$ L of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
4. Repeat steps 1 to 3.
5. Spot centrifuge the reaction tube and then separate the particles on a magnetic tube rack for 1 minute.
6. Remove and discard the supernatant taking care not to disturb the pellet.
7. Add 100  $\mu$ L of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 5 minutes in the water bath sweet spot.
8. Determine conjugated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zetapotential via Laser Doppler Electrophoresis.
9. The particles are approximately 10 mg/mL and are ready for use.



## Non-magnetic particle example procedure

**The following procedure details AnteoTech's optimised process for the activation of 1 mg of 300 nm black dyed polystyrene particles with AnteoBind followed by Cardiac Troponin monoclonal antibody (cTnI mAb) conjugation.**

### Step 1: Particle Activation

1. Determine raw material particle diameter, polydispersity index via Dynamic Light Scattering analysis and zeta potential via Laser Doppler Electrophoresis.
2. Transfer 450 µL of *Particle Activation Solution* to a 1.7 mL reaction tube.
3. Transfer 50 µL (1 mg) of 20 mg/mL particles to the reaction tube.
4. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in a solid medium ultrasonicator.
5. Incubate for 16 hours at room temperature on a tube rotator at 25 rpm.

### Step 2: Activated particle wash

1. Separate the particles via centrifugation at 10,000 RCF, 20 °C and for 10 minutes.
2. Remove 475 µL of the supernatant and discard taking care not to disturb the pellet.
3. Add 475 µL of *Particle Wash Solution* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
4. Separate the particles via centrifugation at 10,000 RCF, 20 °C and for 10 minutes.
5. Remove 475 µL of the supernatant and discard taking care not to disturb the pellet.
6. Add 475 µL of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
7. Repeat steps 4 to 6.
8. Separate the particles via centrifugation at 10,000 RCF, 20 °C and for 10 minutes.
9. Remove 475 µL of the supernatant and discard taking care not to disturb the pellet.
10. Add 225 µL of *Conjugation Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
11. Determine activated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zeta potential via Laser Doppler Electrophoresis.

### Step 3: Particle Conjugation

1. Prepare 400 µg/mL cTnI mAb with 200 µg/mL BSA in 250 µL of *Conjugation Buffer*.
2. Add the 250 µL of washed particles to the 250 µL of conjugation solution.
3. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
4. Incubate for 1 hour at room temperature on a tube rotator at 25 rpm.

### Step 4: Particle Blocking

1. Prepare 10% (w/v) BSA in *Blocker Diluent*.
2. Add 50 µL of the 10% (w/v) BSA directly to the particle reaction tube.
3. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
4. Incubate for 1 hour at room temperature on a tube rotator at 25 rpm.



### Step 5: Storage of Conjugated Particles

1. Separate the particles via centrifugation at 10,000 RCF, 20 °C and for 10 minutes.
2. Remove 475 µL of the supernatant and discard taking care not to disturb the pellet.
3. Add 475 µL of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
4. Repeat steps 1 to 3.
5. Separate the particles via centrifugation at 10,000 RCF, 20 °C and for 10 minutes.
6. Remove 475 µL of the supernatant and discard taking care not to disturb the pellet.
7. Add 75 µL of *Storage Buffer* to the particles. Vortex-mix for 10 seconds and then ultrasonicate for 3 rounds of 10 seconds in the titanium sonotrode.
8. Determine conjugated particle diameter, polydispersity index via Dynamic Light Scattering analysis and zeta potential via Laser Doppler Electrophoresis.
9. The particles are approximately 10 mg/mL and are ready for use.



## Trouble Shooting

Issue	Possible Cause(s)	Recommendations
<b>Aggregation</b>	Insufficient sample mixing	Always vortex mix samples for at least 10 seconds.
	Particles not appropriately dispersed	Optimise ultrasonication parameters. AnteoTech recommends liquid medium ultrasonication at 384W or solid medium ultrasonication at 12W.
	Particles are unstable	Complete <i>Optional Step: Particle Pre-Treatment</i> prior to particle activation. Contact AnteoTech Technical Support if issue persists.
	Conjugation efficacy suboptimal	Attempt co-conjugation: Add Blocker Agent during <i>Step 3: Particle Conjugation</i> . Contact AnteoTech Technical Support for further details.
<b>Non-specific signal</b>	Inappropriate blocking	Optimise Blocker Agent. AnteoTech recommends 10% (w/v) BSA in the provided <i>A-CMPBDF1: Blocker Diluent</i> . Alternative blocker agents include but are not limited to, casein, fish skin gelatine, and synthetic blockers. Contact AnteoTech Technical Support for further details.
<b>Conjugate not stable</b>	Biomolecule has limited shelf life	AnteoBind™ activation does not protect against biomolecule degradation related to shelf-life limitations. An alternative biomolecule supplier may be required.
	Inappropriate Conjugation Buffer used	Use the Conjugation Buffer provided with the kit. Contact AnteoTech Technical Support for further details.
	Inappropriate Storage Buffer used	Use the Storage Buffer provided with the kit. Additives such as surfactant and/or sugar may be required for further stability. Contact AnteoTech Technical Support for further details.
<b>Loss of particles</b>	Inappropriate centrifugal separation	Use appropriate centrifuge settings and rotors for the particle type and sample volumes being processed. Contact AnteoTech Technical Support for further details.
	Inappropriate magnetic separation	Ensure that the magnetic separator is appropriate for the particle type and sample volume being processed. Limit the exposure of particles to magnetic forces. Overexposure may induce permanent magnetisation and irreversible aggregation of particles. Contact AnteoTech Technical Support for further details.
	Pipetting	Take care not to disturb the particle pellet during supernatant removal. Do not directly aim the pipette tip at the pellet or excessively agitate the supernatant.
	Prolonged storage	Suspend particles thoroughly before use. Vortex mix for at least 10 seconds followed by ultrasonication. The Storage Buffer may need to be optimised. Contact AnteoTech Technical Support for further details.